Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tandem Diabetes Care (TNDM) Shares Outstanding (Diluted Average) (2018 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Shares Outstanding (Diluted Average) for 8 consecutive years, with $67.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Diluted Average) rose 2.69% year-over-year to $67.0 million, compared with a TTM value of $67.0 million through Sep 2025, up 2.69%, and an annual FY2024 reading of $66.2 million, up 1.83% over the prior year.
  • Shares Outstanding (Diluted Average) was $67.0 million for Q3 2025 at Tandem Diabetes Care, roughly flat from $67.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $67.0 million in Q2 2025 and bottomed at $62.4 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $65.0 million, with a median of $65.0 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) grew 9.29% in 2021, then decreased 2.56% in 2022.
  • Year by year, Shares Outstanding (Diluted Average) stood at $64.3 million in 2021, then fell by 0.32% to $64.1 million in 2022, then increased by 1.28% to $65.0 million in 2023, then increased by 1.83% to $66.2 million in 2024, then rose by 1.33% to $67.0 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for TNDM at $67.0 million in Q3 2025, $67.0 million in Q2 2025, and $66.4 million in Q1 2025.